• Explore /
  • Poster
  • / Rego-SARC: Activity and safety of regorafenib (RE) in patients with metastatic soft-tissue sarcoma (STS) previously treated with anthracyclin-based chemotherapy—A multinational, randomized, placebo-controlled phase II trial.

Rego-SARC: Activity and safety of regorafenib (RE) in patients with metastatic soft-tissue sarcoma (STS) previously treated with anthracyclin-based chemotherapy—A multinational, randomized, placebo-controlled phase II trial.

Abstract Poster

Authors

null

Stephanie Clisant

Centre Oscar Lambret, Lille, France

Stephanie Clisant , Nicolas Penel , Bernadette Lieg-Atzwanger , Viktor Gruenwald , Ferdinand Ploner , Sophie Taieb , Marie Vanseymortier , Axel Le Cesne , Wolfgang Eisterer , Olivier Mir , Antoine Italiano , Pierre Arvis , Andrew Kramar , Jean-Yves Blay , Thomas Brodowicz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

ClinicalTrials.gov: NCT01900743

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS10602)

DOI

10.1200/jco.2014.32.15_suppl.tps10602

Abstract #

TPS10602

Poster Bd #

308A

Abstract Disclosures

Similar Posters

First Author: Nicolas Penel

First Author: Marie-Cecile Le Deley

First Author: Desmond Yip

First Author: Yoon-Koo Kang